Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr (Q46898523)
Jump to navigation
Jump to search
scientific article published in February 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr |
scientific article published in February 2006 |
Statements
1 reference
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr (English)
1 reference
1 reference
Pieter Sonneveld
1 reference
William R Friedenberg
1 reference
Montserrat Rue
1 reference
Emily A Blood
1 reference
William S Dalton
1 reference
Chaim Shustik
1 reference
Philip R Greipp
1 reference
1 February 2006
1 reference
1 reference
106
1 reference
4
1 reference
830-838
1 reference
Identifiers
1 reference
1 reference